| Name | Ensartinib hydrochloride |
| Description | Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations. It potently inhibits both wild-type ALK and ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM. |
| In vitro | Ensartinib potently inhibits both wild-type ALK and all evaluated ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM. Besides ALK, ensartinib also potently inhibits GOPC-ROS1, TPM3-TRKA, and TRKC with an IC50 of <1 nM, and inhibits EphA1, EphA2, EphB1 and c-MET with an IC50 of 1-10 nM[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 33 mg/mL (52.02 mM)
|
| Keywords | X 396 | X396 | Cluster of differentiation 246 | Ensartinib | Inhibitor | CD246 | X-396 | Ensartinib Hydrochloride | Anaplastic lymphoma kinase (ALK) | Anaplastic lymphoma kinase | c-Met/HGFR | ALK tyrosine kinase receptor | Ensartinib hydrochloride | X-396 Dihydrochloride | X396 Dihydrochloride | inhibit | X 396 Dihydrochloride | Ensartinib Dihydrochloride |
| Inhibitors Related | SB-431542 | DMH-1 | Larotrectinib sulfate | L-Ascorbic acid 2-phosphate trisodium | Crizotinib | Amitriptyline hydrochloride | Ceritinib | 7,8-Dihydroxyflavone | Diosmetin | GW 441756 | Cabozantinib S-malate | A 83-01 |
| Related Compound Libraries | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
